Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 2, 2004, Pages 246-255

  Cipollone, Francesco ^a   Rocca, Bianca ^b   Patrono, Carlo ^c,d  

^a UNIVERSITY OF CHIETI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Atherothrombosis; COX 2; COX inhibitors; Inflammatory cells; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYCLOOXYGENASE 2; IRBESARTAN; NAPROXEN; PROSTANOID; ROFECOXIB; SIMVASTATIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ATHEROTHROMBOSIS; BIOSYNTHESIS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; INFLAMMATORY CELL; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SHORT SURVEY; THROMBOCYTE; THROMBOSIS;

ANIMALS; ARTERIOSCLEROSIS; CYCLOOXYGENASE 2; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THROMBOSIS;

EID: 1042268032     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000104005.92603.f2     Document Type: Short Survey

References (115)

1. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119:39S-63S.
2. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest. 2001;107:1491-1495.
3. Kozak KR, Crews BC, Morrow JD, Wamg LH, Ma YH, Weinander R, Jakobsson PJ, Marnett LJ. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem. 2002;277:44877-44885.
4. FitzGerald GA, Patrono C. The coxibs: selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
5. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med. 1999; 340:115-126.
6. McEver R. Adhesive interactions of leukocyte, platelets and vessel wall during hemostasis and inflammation. Thromb Haemostas. 2001;86: 746-756.
7. Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, Edwards D, Hardy M, Isakson P, Masferrer JL. Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol. 2002;66:13-18.
8. Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand. 2001;173:35-43.
9. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
10. Hong BK, Kwon HM, Lee BK, Kim D, Kim IJ, Kang SM, Jang Y, Cho SH, Kim HK, Jang BC, Cho SY, Kim HS, Kim MS, Kwon HC, Lee N. Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J. 2000;41:82-88.
11. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-d-eficient mice. Circulation. 2002;105:1816-1823.
12. Maier JA, Barenghi L, Bradamante S, Pagani F. Modulators of oxidized LDL-induced hyperadhesiveness in human endothelial cells. Biochem Biophys Res Commun. 1994;204:673-677.
13. Mahoney TS, Weyrich AS, Dixon DA, McIntyre T, Prescott SM, Zimmerman GA. Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes. Proc Natl Acad Sci U S A. 2001;98:10284-10289.
14. Zimmerman GA. Two by two: the pairings of P-selectin and P-selectin glycoprotein ligand I. Proc Natl Acad Sci U S A. 2001;98:10023-10024.
15. Von Der Thusen JH, Kuiper J, Van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev. 2003;55:133-166.
16. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-1103.
17. Pontsler AV, St Hilaire A, Marathe GK, Zimmerman GA, McIntyre TM. Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor γ and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem. 2002;277:13029-13036.
18. Fyrnys B, Claus R, Wolf G, Deigner HP. Oxidized low density lipoprotein stimulates protein kinase C (PKC) activity and expression of PKC-isotypes via prostaglandin-H-synthase in P388D1 cells. Adv Exp Med Biol. 1997;407:93-98.
19. Ardans JA, Economou AP, Martinson JM Jr., Zhou M, Wahl LM. Oxidized low-density and high-density lipoproteins regulate the production of matrix metalloproteinase-1 and -9 by activated monocytes. J Leukoc Biol. 2002;71:1012-1018.
20. Barrios-Rodiles M, Tiraloche G, Chadee K. Lipopolysaccharide modulates cyclooxygenase-2 transcriptionally and posttranscriptionally in human macrophages independently from endogenous IL-1β and TNF-α. J Immunol. 1999;166:963-969.
21. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T. Induction of cyclooxygenase-2 by interleukin-1α. Evidence for post-transcriptional regulation. J Biol Chem. 1994;269:11769-11775.
22. Arias-Negrete S, Keller K, Chadee K. Proinflammatory cytokines regulate Cyclooxygenase-2 mRNA expression in human macrophages. Biochem Biophys Res Commun. 1995;208:582-589.
23. Newton R, Kuitert LM, Bergmann M, Adcock IM, Barnes PJ. Evidence for involvement of NF-κB in the transcriptional control of COX-2 gene expression by IL-1β. Biochem Biophys Res Commun. 1997;237:28-32.
24. Yamamoto K, Arakawa T, Ueda N, Yamamoto S. Transcriptional roles of nuclear factor κB and nuclear factor-interleukin-6 in the tumor necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem. 1995;270:31315-31320.
25. Gou Q, Liu CH, Ben-Av P, Hla T. Dissociation of basal turnover and cytokine-induced transcript stabilization of the human cyclooxygenase-2 mRNA by mutagenesis of the 3′-untranslated region. Biochem Biophys Res Commun. 1998;242:508-512.
26. Niiro H, Otsuka T, Ogami E, Yamaoka K, Nagano S, Akahoshi M, Nakashima H, Arinobu Y, Izuhara K, Niho Y. MAP kinase pathways as a route for regulatory mechanisms of IL-10 and IL-4 which inhibit COX-2 expression in human monocytes. Biochem Biophys Res Commun. 1998;250:200-205.
27. Porreca E, Reale M, Di Febbo C, Di Gioacchino M, Barbacane RC, Castellani ML, Baccante G, Conti P, Cuccurullo F. Down regulation of cyclooxygenase-2 (COX-2) by interleukin-1 receptor antagonist in human monocytes. Immunology. 1996;89:424-429.
28. Hallenbeck JM. The many faces of tumor necrosis factor in stroke. Nat Med. 2002;8:1363-1368.
29. 2+ influx, synergism with platelet-activating factor and significance for chemotaxis. J Biol Chem. 1994;269:4746-4753.
30. Kreuzer J, Denger S, Jahn L, Bader J, Ritter K, von Hodenberg E, Kubler W. LDL stimulates chemotaxis of human monocytes through a cyclooxygenase-dependent pathway. Arterioscler Thromb Vasc Biol. 1996;16:1481-1487.
31. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A. 2001;98:3358-3363.
32. Olesen M, Kwong E, Meztli A, Kontny F, Seljeflot I, Arnesen H, Lyngdorf L, Falk E. No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J. 2002;36: 362-367.
33. Rott D, Zhu J, Burnett MS, Zhou YF, Zalles-Ganley A, Ogunmakinwa J, Epstein SE. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol. 2003;41:1812-1819.
34. Cipollone F, Ganci A, Greco A, Panara MR, Pasquale M, Di Gregorio D, Porreca E, Mezzetti A, Cuccurullo F, Patrignani P. Modulation of aspirin-insensitive eicosanoid biosynthesis by 6-methyl-prednisolone in unstable angina. Circulation. 2003;107:55-61.
35. Mehrabian M, Allayee H, Wong J, Shih W, Wang X, Shaposhnik Z, Funk CD, Lusis AJ. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002; 91:120-126.
36. Cipollone F, Mezzetti A, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ucchino S, Cuccurullo F, Prescott SM, Stafforini D. Identification of 5-lipoxygenase as a major gene contributing to atherosclerotic plaque instability in humans. Circulation. In press.
37. Maloney CG, Kutchera WA, Albertine KH, McIntyre TM, Prescott SM, Zimmerman GA. Inflammatory agonists induce cyclooxygenase type 2 expression by human neutrophils. J Immunol. 1998;160:1402-1410.
38. Pouliot M, Gilbert C, Borgeat P, Poubelle PE, Bourgoin S, Creminon C, Maclouf J, McColl SR, Naccache PH. Expression and activity of prostaglandin endoperoxide synthase-2 in agonist-activated human neutrophils. FASEB J. 1998;12:1109-1123.
39. Niiro H, Otsuka T, Izuhara K, Yamaoka K, Ohshima K, Tanabe T, Hara S, Nemoto Y, Tanaka Y, Nakashima H, Niho Y. Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood. 1997;89:1621-1628.
40. Tedgui A, Mallat Z. Anti-inflammatory mechanism in the vascular wall. Circ Res. 2001;88:877-887.
41. Mertz PM, DeWitt DL, Stetler-Stevenson WG, Wahl LM. Interleukin 10 suppression of monocyte prostaglandin H synthase-2: mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J Biol Chem. 1994;269:21322-21329.
42. McAdam BF, Mardini IA, Habib A, Burke A, Lawson JA, Kapoor S, FitzGerald GA. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest. 2000;105:1473-1482.
43. Ishizuka T, Kawakami M, Hidaka T, Matsuki Y, Takamizawa M, Suzuki K, Kurita A, Nakamura H. Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin Exp Immunol. 1998;112: 464-470.
44. 2α stimulates endothelial cells to bind monocytes: differences from thromboxane-mediated endothelial activation. FASEB J. 2001;15: 1254-1256.
45. Ishizuka T, Sawada S, Sugama K, Kurita A. Thromboxane A2 (TXA2) receptor blockade suppresses monocyte chemoattractant protein-1 (MCP-1) expression by stimulated vascular endothelial cells. Clin Exp Immunol. 2000;120:71-78.
46. Spagnuolo PJ, Ellner JJ, Hassid A, Dunn MJ. Thromboxane A2 mediates augmented polymorphonuclear leukocyte adhesiveness. J Clin Invest. 1980;66:406-414.
47. Pratico D, FitzGerald GA. Generation of 8-epiprostaglandin F2α by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem. 1996;271: 8919-8924.
48. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330: 1287-1294.
49. Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet. 1999;353:900.
50. Matijevic-Aleksic, N., Sanduja, S. K., Wang, L. H., Wu, K. K. Differential expression of thromboxane A synthase and prostaglandin H synthase in megakaryocytic cell line. Biochim Biophys Acta. 1995;1269: 167-175.
51. Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci (USA). 2002;99:7634-7639.
52. Patrignani P, Sciulli MG, Manarini S, Santini G, Cerletti C, Evangelista V. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol. 1999;50:661-667.
53. Pabla R, Weyrich AS, Dixon DA, Bray PF, McIntyre TM, Prescott SM, Zimmerman GA. Integrin-dependent control of translation: engagement of integrin αIIb β3 regulates synthesis of proteins in activated human platelets. J Cell Biol. 1999;144:175-184.
54. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, Weyrich AS. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J Cell Biol. 2001;154:485-490.
55. 2+-dependent K+ channel in human erythrocytes and alters cell volume and filterability. J Biol Chem. 1996;271:18651-18656.
56. 2+-dependent release of arachidonic acid from mammalian red blood cells. J Biol Chem. 2002;277:21086-21094.
57. Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J, Sanchez E, Broekman MJ, Marcus AJ. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation. 1998;97:350-355.
58. 2 in human endothelial cells by engagement of CD40. Atherosclerosis. 2002; 163:9-16.
59. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
60. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 1996;94:1239-1246.
61. Karim S, Habib A, Levy-Toledano S, Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem. 1996;271: 12042-12048.
62. Barry OP, FitzGerald GA. Mechanisms of cellular activation by platelet microparticles. Thromb Haemost. 1999;82:794-800.
63. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest. 1998;102:136-144.
64. Barry OP, Kazanietz MG, Pratico D, FitzGerald GA. Arachidonic acid in platelet microparticles up-regulates cyclooxygenase-2-dependent prostaglandin formation via a protein kinase C/mitogen-activated protein kinase-dependent pathway. J Biol Chem. 1999;274:7545-7556.
65. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272-277.
66. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A. 1996;93:10417-10422.
67. Houliston RA, Keogh RJ, Sugden D, Dudhia J, Carter TD, Wheeler-Jones CP. Protease-activated receptors upregulate cyclooxygenase-2 expression in human endothelial cells. Thromb Haemost. 2002; 88:321-328.
68. Wohlfeil ER, Campbell WB. 25-Hydroxycholesterol enhances eicosanoid production in cultured bovine coronary artery endothelial cells by increasing prostaglandin G/H synthase-2. Biochim Biophys Acta. 1997; 1345:109-120.
69. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol. 2001;167:2831-2838.
70. Cockerill GW, Saklatvala J, Ridley SH, Yarwood H, Miller NE, Oral B, Nithyanathan S, Taylor G, Haskard DO. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vasc Biol. 1999;19:910-917.
71. Smith LH, Boutaud O, Breyer M, Morrow JD, Oates JA, Vaughan DE. Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro. Arterioscler Thromb Vasc Biol. 2002;22:983-988.
72. Rolland PH, Jouve R, Pellegrin E, Mercier C, Serradimigni A. Alteration in prostacyclin and prostaglandin E2 production: correlation with changes in human aortic atherosclerotic disease. Arteriosclerosis. 1984; 4:70-78.
73. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-845.
74. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999;155:1281-1291.
75. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, Yacoub MH, Polak JM. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999;19:646-655.
76. Wong E, Huang JQ, Tagari P, Riendeau D. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis. 2001;157:393-402.
77. 2-dependent plaque instability. Circulation. 2001;104: 921-927.
78. 2 synthesis, and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg. 1997;25:810-815.
79. Welgus HG, Campbell EJ, Curry JD, Eisen AZ, Senior RM, Wilhelm SM, Goldberg GI. Neutral metalloproteinases produced by human mononuclear phagocytes: enzyme profile, regulation and cellular differentiation. J Clin Invest. 1990;86:1496-1502.
80. 2, and matrix metalloproteinases production by human monocytes. Arch Biochem Biophys. 1994;310:481-488.
81. Loftus IM, Naylor R, Goodall S, Crowther M, Jones L, Bell PR, Thompson MM. Increased matrix-metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke. 2000;31:40-47.
82. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94: 2493-2503.
83. Mitchell J, Belvisi M, Akarasereenont P, Robbins RA, Kwon OJ, Croxtall J, Barnes PJ, Vane JR. Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone. Br J Pharmacol. 1994;113:1008-1014.
84. 2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem. 2000;275:32783-32792.
85. Jakobsson PJ, Thorén S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A. 1999;96:7220-7225.
86. 2. J Biol Chem. 2001;276:34918-34927.
87. 2-dependent induction of cyclooxygenase-2 in macrophages. J Biol Chem. 1999;274:25967-25970.
88. Bucciarelli L, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern D, Schmidt AM. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein-E-null mice. Circulation. 2002;106:2827-2835.
89. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation. 2003;108:1070-1077.
90. 2-dependent plaque instability. Circulation. 2002;106:1144. Abstract.
91. 2 synthesis. J Biol Chem. 1997;272: 31065-31072.
92. Cipollone F, Marini M, Fazia M, Iezzi A, De Cesare D, Pini B, Ucchino S, Spigonardo F, Bajocchi G, Prontera C, Chiarelli F, Cuccurullo F, Mezzetti A. The balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaques instability in humans. Arterioscler Thromb Vasc Biol. 2002;22:878a. Abstract.
93. 2 and the ligation of PPARγ. J Clin Invest. 2003;112:945-955.
94. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001;108:25-30.
95. 2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem. 2002;277: 44147-44154.
96. Cipollone F, Fazia M, Iezzi A, Cuccurullo C, Zucchelli M, Ucchino S, Bucci M, Mezzetti A. The prostaglandin E receptor subtype EP4 mediates PGE2-dependent plaque instability in humans. Eur Heart J. 2003;24:P2198. Abstract.
97. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ. A common promoter variant in cyclooxygenase-2 represses gene expression: evidence for a role in the acute phase inflammatory response. Arterioscler Thromb Vasc Biol. 2002;22:1631-1636.
98. Cipollone F, Patrono C. Cyclooxygenase-2 polymorphism. Putting a brake on the inflammatory response to vascular injury? Arterioscler Thromb Vasc Biol. 2002;22:1516-1518.
99. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, Pini B, Ursi S, Vitullo G, Avema M, Arca M, Montali A, Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, and Mezzetti A. A polymorphism in the cyclooxygenase-2 gene as an inherited protective factor against myocardial infarction and stroke. Circulation. In press.
100. Vejar M, Fragasso G, Hackett D, Lipkin PD, Maseri A, Born GVR, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemostas. 1990;63:163-168.
101. Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in unstable angina. Circulation. 1997;96:1109-1116.
102. Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, Davì G, Cuccurullo F, Patrono C. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation. 2000;102:1007-1013.
103. Van Kooten F, Ciabattoni G, Koudstaal PJ, Grobbee DE, Kluft C, Patrono C. Increased thromboxane biosynthesis is associated with post-stroke dementia. Stroke. 1999;30:1542-1547.
104. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-1655.
105. García Rodríguez LA, Hernandez-Díaz S. Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003; 14:240-246.
106. Bak S, Andersen M, Tsiropoulos I, Garcia Rodriguez LA, Hallas J, Christensen K, Gaist D. Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study. Stroke. 2003;34: 379-386.
107. Baigent C, Patrono C. Selective cyclooxygenase-2 inhibitors, aspirin and cardiovascular disease: a re-appraisal. Arthritis Rheum. 2003;48:12-20.
108. Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D, Ucchino S, Spigonardo F, Bajocchi G, Bei R, Muraro R, Artese L, Piattelli A, Chiarelli F, Cuccurullo F, Mezzetti A. Suppression of the functionally coupled cyclooxygenase-2/PGE synthase as a basis of sim-vastatin-dependent plaque stabilization in humans. Circulation. 2003; 107:1479-1485.
109. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez A, Tunon J, Hernandez-Vargas P, Blanco-Colio LM, Mas S, Aparicio C, Ortega L, Vivanco F, Gerique JG, Diaz C, Hernandez G, Egido J. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 2002;160:49-58.
110. Degraeve F, Bolla M, Blaie S, Creminon C, Quere I, Boquet P, Levy-Toledano S, Bertoglio J, Habib A. Modulation of COX-2 expression by statins in human aortic smooth muscle cells: involvement of geranylgeranylated proteins. J Biol Chem. 2001;276:46849-46855.
111. Onhaka K, Numaguchi K, Yamakawa T, Inagami T. Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension. 2000;35:68-75.
112. Hu ZW, Kerb R, Shi XY, Wei-Lavery T, Hoffman BB. Angiotensin 11 increases expression of cyclooxygenase-2: implications for the function of vascular smooth muscle cells. J Pharmacol Exp Ther. 2002;303:563-573.
113. 2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol. 1995;76:8D-13D.
114. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586-1593.
115. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type I receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol. 2001;37: 440-444.